ArticleOncotarget2017
Long-term prognosis of Guillain-Barré syndrome not determined by treatment options?
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Miller Fischer syndrome after COVID-19 infection and vaccine: a systematic review.Acta neurologica Belgica · 2023Pooled it
- Review
- Patient Outcomes Among Medicare Beneficiaries With Guillain-Barré Syndrome.Journal of the peripheral nervous system : JPNS · 2026Article
- Fusion of molecular mimicry, epigenetic predisposition, and new onset GBS: a narrative review of current understanding and future directions.Annals of medicine and surgery (2012) · 2026Review
- Article
- Article
- Evolving understanding of Guillain-Barré syndrome pathophysiology and the central role of the classical complement pathway in axonal injury.Frontiers in neurology · 2025Article
- Autoimmune diseases refractory to corticosteroids and immunosuppressants.Frontiers in immunology · 2024Review
- Guillain-Barre syndrome (GBS) associated with COVID-19 infection that resolved without treatment in a child.BMJ case reports · 2022Article
- Article
- Axonal variants of Guillain-Barré syndrome: an update.Journal of neurology · 2021Review
- Exploring the experiences of having Guillain-Barré Syndrome: A qualitative interview study.Health expectations : an international journal of public participation in health care and health policy · 2020Article
- Prevalence and outcomes of Guillain-Barré syndrome among pediatrics in Saudi Arabia: a 10-year retrospective study.Neuropsychiatric disease and treatment · 2019Article
- Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection.PloS one · 2019Article
- Possible Association of Papillophlebitis with Guillain-Barré Syndrome: Case Report.Turkish journal of ophthalmology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long-term follow-up system for Guillain-Barré syndrome (GBS) is not well established worldwide. In our study, the preliminary data of the long-term prognosis of GBS are collected to explore the prognosis of GBS and the effect of intravenous immunoglobulin (IVIg) treatment.
methodsThe follow-up data of 186 patients with GBS admitted from 2003 to 2013 were collected in 2015
resultsThe mortality rates were 2.15%, 5.45% and 7.89% at discharge, 2-5 years and 6-10 years after disease, respectively. The GBS disability scale score improved dramatically from discharge to 2-12 years after the acute phase. The self-limitation, the spontaneous recovery of disease, occurred both at acute phase and 2-5 years after discharge. Comparisons between IVIg-treated patients and GBS patients who only received supportive care revealed no significant difference of long-term prognosis.
conclusionThe long-term prognosis of GBS appears not to be influenced by treatment options. The long-term improvement of IVIg treated-patients might be due to the self-limitation of GBS per se instead of the IVIg treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.